Mintz has guided long-standing client Asimov in its $200 million fundraising aimed to scale the company’s tools and services business in biologics, cell/gene therapies, and RNA.

Boston-based Asimov is a synthetic biology company building tools to design living systems. It was founded by bioengineers from MIT and Boston University.

Part of the fundraising included a $175 million Series B round led by Canada Pension Plan Investment Board (CPP Investments), with participation from Fidelity Management & Research Company, KDT, Casdin Capital, Pillar, and Andreessen Horowitz (a16z), who led Asimov’s seed round.

Mintz Member Joshua Fox led the team advising Asimov on the fundraising, which included Associates Kaoru Suzuki and Michael Katz.

Mintz, a leading life sciences law firm, represents therapeutics, vaccine, medical device and systems, research tools and diagnostics companies, as well as investment banks, venture capital firms and other investors. Our work for these clients encompasses transactional, health care regulatory, intellectual property, litigation, employment, real estate and other matters. We are embedded in the global life sciences ecosystem and provide industry leaders with practical solutions to business-critical challenges, helping them achieve their strategic and business goals.

• $22B+ in transactions handled in 2021 for industry clients, including public offerings, joint ventures, licensing and complex collaborations, mergers and acquisitions, divestitures, distribution deals, and private financings
• Advise on the complete spectrum of FDA regulations, from clinical trials through product launch and beyond, including product approvals, labeling, and supply and distribution agreements
• Prosecute patents to issuance (more than 30 patent team members have biology or chemistry PhDs), navigate trademarks through the USPTO and health regulatory bodies, and defend patent, trade secret and trademark rights in trial courts and at the USPTO
• Successful track record of helping life sciences clients avoid — and when necessary resolve —securities class actions, governmental investigations, and disputes with collaboration/licensing partners